Compare HIMX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | SNDX |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2006 | 2014 |
| Metric | HIMX | SNDX |
|---|---|---|
| Price | $20.63 | $20.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $38.69 |
| AVG Volume (30 Days) | ★ 4.9M | 1.6M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $14.94 | $107.19 |
| Revenue Next Year | $7.79 | $41.88 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $6.85 | $8.59 |
| 52 Week High | $21.80 | $25.59 |
| Indicator | HIMX | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 45.28 |
| Support Level | $7.63 | $19.35 |
| Resistance Level | N/A | $22.33 |
| Average True Range (ATR) | 1.44 | 1.09 |
| MACD | 0.89 | 0.05 |
| Stochastic Oscillator | 89.48 | 53.12 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.